Study of ASP546C for stomach, pancreas, and other cancers
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called ASP546C in people with certain advanced cancers that have a specific marker (CLDN18.2). It aims to see if the drug can shrink or slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: stomach, esophagus, pancreas, bile duct, colon, lung, ovary, or breast cancer that has spread or cannot be removed by surgery.
- Your tumor has a protein called CLDN18.2.
- You have already had at least one prior cancer treatment.
- You are able to do daily activities (ECOG 0 or 1).
- You are not pregnant and agree to use birth control during and for a period after the study.
- You have enough tumor tissue available for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests ASP2138 alone or with other cancer medicines in adults with stomach (including GEJ) or pancreatic cancer. You may be eligible if your tumor has a specific protein marker and your health tests and scan results meet safety requirements.
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
This study tests an experimental drug, ASP2138, given before surgery for pancreatic cancer that is still removable. After surgery, you will receive standard chemotherapy. The goal is to see if adding ASP2138 before surgery helps improve outcomes.
This trial tests a new medication that targets a specific protein (CLDN18.2) found on some cancer cells. It may help people with advanced or metastatic stomach, esophageal, or pancreatic cancer who have already tried other treatments.
This trial tests a new drug called CT0494BCP for advanced stomach cancer that has not responded to previous treatments. The drug targets a protein called CLDN18.2, which is found on many stomach cancer cells, and aims to help your immune system fight the cancer.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.